Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

The Lancet. Child & adolescent health·2026
Same author

Education Research: The Future of Child Neurology Residency Training: The Perspective of a Child Neurology Society Task Force.

Neurology. Education·2026
Same author

Multifrequency Electrical Impedance Myography Enhanced with Machine Learning for Screening Patients with Neuromuscular Disorders.

Annals of biomedical engineering·2026
Same author

Deficiency of muscular dystrophy-related gene JAG2 causes NOTCH signaling dysfunction in muscle stem cells.

The Journal of clinical investigation·2026
Same author

Design and initial characterization of a novel mini-promoter for gene therapies targeting the central nervous system.

Molecular therapy. Advances·2026
Same author

Updating <i>Neurology</i>® Journals' Policies on AI Use, Reporting of Genetic Studies, and Protocols for Systematic Review.

Neurology·2026
Same journal

Join AANEM.

Muscle & nerve·2026
Same journal

Targeted Muscle Reinnervation for Management and Prevention of Symptomatic Neuroma.

Muscle & nerve·2026
Same journal

AANEM News & Insights.

Muscle & nerve·2026
Same journal

Fat-Fraction Quantification Using Three-Point Dixon Technique in Duchenne Muscular Dystrophy and Its Correlation With Clinical Progression and Genotypic Characteristics: A Single Centre One-Year Prospective Study.

Muscle & nerve·2026
Same journal

Characterizing Combined Central and Peripheral Demyelination-Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis.

Muscle & nerve·2026
Same journal

Electrical Modalities in the Rehabilitation of Peripheral Nerve Injuries: State of the Literature and Current Clinical Applications.

Muscle & nerve·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Juvenile myasthenia gravis.

Laura M Chiang1, Basil T Darras, Peter B Kang

  • 1Department of Neurology, Children's Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.

Muscle & Nerve
|February 21, 2009
PubMed
Summary
This summary is machine-generated.

Juvenile myasthenia gravis (JMG) differs from adult forms in epidemiology and presentation. Treatment for JMG prioritizes steroid-sparing options due to long-term risks in children and adolescents.

Related Experiment Videos

Last Updated: Jun 25, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Juvenile myasthenia gravis (JMG) shares pathophysiologic origins with adult myasthenia gravis.
  • Key distinctions exist in epidemiology, clinical presentation, and treatment strategies between pediatric and adult populations.

Purpose of the Study:

  • To delineate the unique epidemiological, diagnostic, and therapeutic aspects of juvenile myasthenia gravis.
  • To highlight differences in management compared to adult myasthenia gravis, considering long-term outcomes.

Main Methods:

  • Comparative analysis of epidemiological data across pre- and postpubertal age groups.
  • Review of diagnostic evaluations, including specialized techniques for pediatric single-fiber electromyography.
  • Assessment of therapeutic interventions, focusing on steroid-sparing agents and alternative treatments.

Main Results:

  • Gender ratios and seropositivity rates vary between pre- and postpubertal JMG.
  • Diagnostic procedures are similar to adults, with adaptations for younger patients.
  • Intravenous immunoglobulin (IVIg) and plasmapheresis are emphasized due to long-term steroid concerns.

Conclusions:

  • Juvenile myasthenia gravis requires tailored management strategies.
  • Careful consideration of long-term consequences influences therapeutic decisions in pediatric patients.
  • Steroid-sparing agents are valuable but necessitate caution regarding malignancy risk.